Table 1.
Discovery Set | Validation Set | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Plasma/Urine | Plasma | Urine | ||||||||||
Level | Normal | Benignant | Borderline | Malignant | Normal | Benignant | Borderline | Malignant | Normal | Benignant | Borderline | Malignant |
n | 40 | 36 | 13 | 74 | 36 | 14 | 1 | 21 | 40 | 45 | 7 | 76 |
Age (mean (sd)) | 39.67 (8.50) | 43.33 (14.55) | 46.54 (17.59) | 56.19 (9.77) | 40.83 (10.17) | 44.36 (17.08) | 34 | 54.76 (11.84) | 45.85 (9.72) | 43.51 (14.81) | 38.86 (13.87) | 53.75 (10.00) |
CA125 (mean (sd)) | 8.35 (5.81) | 83.45 (234.82) | 183.88 (326.63) | 1254.34 (1597.27) | 6.31 (3.78) | 60.96 (146.43) | 250.2 | 938.10 (1243.80) | 7.65 (6.12) | 94.57 (321.85) | 193.12 (140.65) | 1078.35 (1195.30) |
HE4 (mean (sd)) | - | 53.71 (13.77) | 84.34 (66.89) | 440.62 (447.08) | - | 52.28 (10.99) | 74.06 | 389.75 (472.48) | - | 49.93 (23.99) | 93.45 (40.62) | 519.58 (405.72) |
FIGO (%) | - | - | - | - | - | - | - | - | - | - | - | |
I | - | - | 8 (61.5) | 8 (10.8) | - | - | - | 2 (9.5) | - | - | 6 (85.7) | 13 (17.1) |
II | - | - | 1 (7.7) | 9 (12.2) | - | - | 1 (100.0) | 3 (14.3) | - | - | - | 7 (9.2) |
III | - | - | 2 (15.4) | 50 (67.6) | - | - | - | 15 (71.4) | - | - | 1 (14.3) | 51 (67.1) |
IV | - | - | - | 7 (9.5) | - | - | - | - | - | - | - | 5 (6.6) |
NA | 40 (100.0) | 36 (100.0) | 2 (15.4) | - | 36 (100.0) | 14 (100.0) | - | 1 (4.8) | 40 (100.0) | 45 (100.0) | - | - |
Pathology (%) | ||||||||||||
HGSOC | - | - | - | 57 (77.0) | - | - | - | 14 (70.0) | - | - | - | 56 (73.7) |
OCS | - | - | - | 1 (1.4) | - | - | - | 3 (15.0) | - | - | - | 3 (3.9) |
OCCC | - | - | - | 3 (4.1) | - | - | - | 2 (10.0) | - | - | - | 4 (5.3) |
OEC | - | - | - | - | - | - | - | - | - | - | - | 4 (5.3) |
Others | - | - | - | 13 (17.5) | - | - | - | 2 (10.0) | - | - | - | 9 (11.8) |
Abbreviations: HGSOC: High-grade serous ovarian cancer; OCS: ovarian carcinosarcoma; OCCC: ovarian clear cell carcinoma; OEC: ovarian endometrioid adeno-carcinoma.